Our history

Autolus is founded by Dr Martin Pule and is spun-out from UCL

£30 million Series A investment from founding investor Syncona

Publication of RQR8 Safety Switch in Blood

Secures £40 million Series B financing

Doses 1st patients for AUTO1 for pediatric ALL and AUTO6 for Neuroblastoma

Collaboration with CGT Catapult Manufacturing Facility

Doses 1st patients for AUTO2 for Multiple Myeloma, AUTO3 for pALL and DLBCL and AUTO1 for adult ALL

Publication of AUTO4 in Nature Medicine 

Secures $80 million Series C financing

Successful IPO on Nasdaq raising a total of $160.4 million

Publication of Rapacasp9 safety switch in Molecular Therapy 

Opens an office in Maryland, USA

Secures $109 million in public offering

Publication of AUTO1 mechanism of action and pALL Ph1 in Nature Medicine 

Secures $74.2 million in public offering

Starts FELIX trial for AUTO1 in adult ALL

Publication of AUTO6 neuroblastoma Ph1 in Science Translational Medicine 

Publication of AUTO1 mechanism of action in Nature Cancer

Secures $100 million in public offering

Publication of AUTO1 adult ALL Ph1 in Journal of Clinical Oncology

Initiates strategic collaboration with Blackstone, securing up to $250 million to develop obe-cel in adult ALL

Pivotal Phase 2 FELIX study meets primary end point

Secures $164m in public offering

Receives of $70m from Blackstone Life Sciences

Secures licensing deals with Moderna and BMS

Handover of first clean rooms in Stevenage

Presents pivotal phase 2 obe-cel data (FELIX study) for adult ALL at ASCO and EHA

Secures licensing deal with Cabaletta Bio

Submits BLA to US FDA for obe-cel for patients with r/r adult ALL

Presents updated clinical data (FELIX study) for adult ALL at ASH

Secures a strategic CAR T cell therapy collaboration with BioNTech to advance pipeline and expand late-stage programs 

Secures $350 million in public offering